Novavax COVID-19 vaccine “89.3% effective” in UK clinical trial.
Novavax Inc on Thursday said that its COVID-19 vaccine was 89.3% effective in preventing the coronavirus disease in a clinical trial conducted in the UK.
According to a preliminary analysis, Novavax COVID-19 vaccine was “nearly as effective” in protecting against the more highly-contagious coronavirus variant first discovered in the United Kingdom.
Based on a report on Reuters, a mid-stage clinical trial of the COVID-19 vaccine in South Africa, wherein a potent variant of the virus was common, showed “60% effectiveness” among people who didn’t have HIV.
Following the report, which came on the day the United States reported its first cases of the South African COVID-19 variant, Novavax shares rose 20% in after hours trading.
READ ALSO: Bulk Of COVID-19 Vaccines For PH Will Come From Novavax, Says Galvez
Novavax said that the clinical trial in the United Kingdom, which enrolled 15,000 people aged 18-84 years old, was expected to be used to apply for regulatory review in Britain, the European Union, and other countries. Some 27% of people enrolled in the clinical trial were over age 65.
The United States company announced in a news release that the said study took place as the more highly-transmissible UK COVID-19 variant was circulating, and the preliminary analysis suggested that the coronavirus vaccine was “85.6% effective” against the said mutation. However, it didn’t provide the study data.
Reuters also reported that the effectiveness of the COVID-19 vaccine in the UK trial was close to that of the two authorized COVID-19 vaccines from Moderna and Pfizer-BioNTech, whose two-dose regimens were around 95% effective at preventing the coronavirus disease in clinical trials.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.
